#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=In this study , exposure to ERAV , as determined by serological testing , was associated with respiratory disease , loss of training days and failure to race in young racehorses .
2-1	14-16	In	_	_	_	_
2-2	17-21	this	abstract[2]	new[2]	coref	6-2[32_2]
2-3	22-27	study	abstract[2]	new[2]	_	_
2-4	28-29	,	_	_	_	_
2-5	30-38	exposure	abstract[3]	new[3]	coref	20-3[150_3]
2-6	39-41	to	abstract[3]	new[3]	_	_
2-7	42-46	ERAV	abstract[3]|abstract	new[3]|new	coref	3-13
2-8	47-48	,	abstract[3]	new[3]	_	_
2-9	49-51	as	abstract[3]	new[3]	_	_
2-10	52-62	determined	abstract[3]	new[3]	_	_
2-11	63-65	by	abstract[3]	new[3]	_	_
2-12	66-77	serological	abstract[3]|abstract[5]	new[3]|new[5]	_	_
2-13	78-85	testing	abstract[3]|abstract[5]	new[3]|new[5]	_	_
2-14	86-87	,	_	_	_	_
2-15	88-91	was	_	_	_	_
2-16	92-102	associated	_	_	_	_
2-17	103-107	with	_	_	_	_
2-18	108-119	respiratory	abstract[6]	new[6]	coref	12-1[83_6]
2-19	120-127	disease	abstract[6]	new[6]	_	_
2-20	128-129	,	_	_	_	_
2-21	130-134	loss	event[7]	new[7]	coref	15-13[110_7]
2-22	135-137	of	event[7]	new[7]	_	_
2-23	138-146	training	event[7]|event|time[9]	new[7]|new|new[9]	coref	4-10
2-24	147-151	days	event[7]|time[9]	new[7]|new[9]	_	_
2-25	152-155	and	_	_	_	_
2-26	156-163	failure	event[10]	new[10]	coref	8-21[63_10]
2-27	164-166	to	event[10]	new[10]	_	_
2-28	167-171	race	event[10]	new[10]	_	_
2-29	172-174	in	event[10]	new[10]	_	_
2-30	175-180	young	event[10]|animal[11]	new[10]|new[11]	coref	6-7[0_11]
2-31	181-191	racehorses	event[10]|animal[11]	new[10]|new[11]	_	_
2-32	192-193	.	_	_	_	_

#Text=Monthly screening indicated that the majority of two-year-old horses were exposed to ERAV during the three months after entering the yard .
3-1	194-201	Monthly	abstract[12]	new[12]	_	_
3-2	202-211	screening	abstract[12]	new[12]	_	_
3-3	212-221	indicated	_	_	_	_
3-4	222-226	that	_	_	_	_
3-5	227-230	the	animal[13]	new[13]	coref	4-15[20_13]
3-6	231-239	majority	animal[13]	new[13]	_	_
3-7	240-242	of	animal[13]	new[13]	_	_
3-8	243-255	two-year-old	animal[13]	new[13]	_	_
3-9	256-262	horses	animal[13]	new[13]	_	_
3-10	263-267	were	_	_	_	_
3-11	268-275	exposed	_	_	_	_
3-12	276-278	to	_	_	_	_
3-13	279-283	ERAV	abstract	giv	coref	6-18
3-14	284-290	during	_	_	_	_
3-15	291-294	the	time[15]	new[15]	_	_
3-16	295-300	three	time[15]	new[15]	_	_
3-17	301-307	months	time[15]	new[15]	_	_
3-18	308-313	after	time[15]	new[15]	_	_
3-19	314-322	entering	time[15]	new[15]	_	_
3-20	323-326	the	time[15]|place[16]	new[15]|new[16]	coref	4-20[21_16]
3-21	327-331	yard	time[15]|place[16]	new[15]|new[16]	_	_
3-22	332-333	.	_	_	_	_

#Text=The clinical signs that resulted in an interruption to training were primarily observed after the horses had been in the yard for several weeks and were being prepared for their first race .
4-1	334-337	The	abstract[17]	new[17]	coref	14-1[100_17]
4-2	338-346	clinical	abstract[17]	new[17]	_	_
4-3	347-352	signs	abstract[17]	new[17]	_	_
4-4	353-357	that	abstract[17]	new[17]	_	_
4-5	358-366	resulted	abstract[17]|abstract	new[17]|new	coref|none	11-1[75_0]|4-5[0_182]
4-6	367-369	in	abstract[17]	new[17]	_	_
4-7	370-372	an	abstract[17]|event[18]	new[17]|new[18]	coref	11-13[79_18]
4-8	373-385	interruption	abstract[17]|event[18]	new[17]|new[18]	_	_
4-9	386-388	to	abstract[17]|event[18]	new[17]|new[18]	_	_
4-10	389-397	training	abstract[17]|event[18]|event	new[17]|new[18]|giv	coref	6-43
4-11	398-402	were	_	_	_	_
4-12	403-412	primarily	_	_	_	_
4-13	413-421	observed	_	_	_	_
4-14	422-427	after	_	_	_	_
4-15	428-431	the	animal[20]	giv[20]	coref	5-4[26_20]
4-16	432-438	horses	animal[20]	giv[20]	_	_
4-17	439-442	had	_	_	_	_
4-18	443-447	been	_	_	_	_
4-19	448-450	in	_	_	_	_
4-20	451-454	the	place[21]	giv[21]	coref	7-5[49_21]
4-21	455-459	yard	place[21]	giv[21]	_	_
4-22	460-463	for	place[21]	giv[21]	_	_
4-23	464-471	several	place[21]|time[22]	giv[21]|new[22]	_	_
4-24	472-477	weeks	place[21]|time[22]	giv[21]|new[22]	_	_
4-25	478-481	and	_	_	_	_
4-26	482-486	were	_	_	_	_
4-27	487-492	being	_	_	_	_
4-28	493-501	prepared	_	_	_	_
4-29	502-505	for	_	_	_	_
4-30	506-511	their	person|event[24]	acc|new[24]	ana	10-12
4-31	512-517	first	event[24]	new[24]	_	_
4-32	518-522	race	event[24]	new[24]	_	_
4-33	523-524	.	_	_	_	_

#Text=The susceptibility of young horses to rhinitis virus infection when moved to a new environment and starting to comingle with other horses has been reported previously .
5-1	525-528	The	abstract[25]	new[25]	coref	20-22[157_25]
5-2	529-543	susceptibility	abstract[25]	new[25]	_	_
5-3	544-546	of	abstract[25]	new[25]	_	_
5-4	547-552	young	abstract[25]|animal[26]	new[25]|giv[26]	coref	5-21[31_26]
5-5	553-559	horses	abstract[25]|animal[26]	new[25]|giv[26]	_	_
5-6	560-562	to	abstract[25]	new[25]	_	_
5-7	563-571	rhinitis	abstract[25]|abstract|event[29]	new[25]|new|new[29]	coref	7-12[52_29]
5-8	572-577	virus	abstract[25]|abstract|event[29]	new[25]|new|new[29]	_	_
5-9	578-587	infection	abstract[25]|event[29]	new[25]|new[29]	_	_
5-10	588-592	when	abstract[25]	new[25]	_	_
5-11	593-598	moved	abstract[25]	new[25]	_	_
5-12	599-601	to	abstract[25]	new[25]	_	_
5-13	602-603	a	abstract[25]|abstract[30]	new[25]|new[30]	coref	20-14[0_30]
5-14	604-607	new	abstract[25]|abstract[30]	new[25]|new[30]	_	_
5-15	608-619	environment	abstract[25]|abstract[30]	new[25]|new[30]	_	_
5-16	620-623	and	abstract[25]	new[25]	_	_
5-17	624-632	starting	abstract[25]	new[25]	_	_
5-18	633-635	to	abstract[25]	new[25]	_	_
5-19	636-644	comingle	abstract[25]	new[25]	_	_
5-20	645-649	with	_	_	_	_
5-21	650-655	other	animal[31]	giv[31]	coref	6-14[36_31]
5-22	656-662	horses	animal[31]	giv[31]	_	_
5-23	663-666	has	_	_	_	_
5-24	667-671	been	_	_	_	_
5-25	672-680	reported	_	_	_	_
5-26	681-691	previously	_	_	_	_
5-27	692-693	.	_	_	_	_

#Text=In a seven-year serological study of racehorses in Japan , 69 % of horses that seroconverted to ERAV were two years of age and Black et al. reported that 43 % of horses seroconverted to ERAV within 7 months of entering a training stable in Australia .
6-1	694-696	In	_	_	_	_
6-2	697-698	a	abstract[32]	giv[32]	coref	7-1[48_32]
6-3	699-709	seven-year	abstract[32]	giv[32]	_	_
6-4	710-721	serological	abstract[32]	giv[32]	_	_
6-5	722-727	study	abstract[32]	giv[32]	_	_
6-6	728-730	of	abstract[32]	giv[32]	_	_
6-7	731-741	racehorses	abstract[32]|animal	giv[32]|giv	coref	17-12[128_0]
6-8	742-744	in	abstract[32]	giv[32]	_	_
6-9	745-750	Japan	abstract[32]|place	giv[32]|new	_	_
6-10	751-752	,	_	_	_	_
6-11	753-755	69	person[35]	new[35]	_	_
6-12	756-757	%	person[35]	new[35]	_	_
6-13	758-760	of	person[35]	new[35]	_	_
6-14	761-767	horses	person[35]|animal[36]	new[35]|giv[36]	coref	6-33[0_36]
6-15	768-772	that	person[35]|animal[36]	new[35]|giv[36]	_	_
6-16	773-786	seroconverted	person[35]|animal[36]	new[35]|giv[36]	_	_
6-17	787-789	to	person[35]|animal[36]	new[35]|giv[36]	_	_
6-18	790-794	ERAV	person[35]|animal[36]|abstract	new[35]|giv[36]|giv	coref	6-36
6-19	795-799	were	_	_	_	_
6-20	800-803	two	time[38]	new[38]	_	_
6-21	804-809	years	time[38]	new[38]	_	_
6-22	810-812	of	time[38]	new[38]	_	_
6-23	813-816	age	time[38]|abstract	new[38]|new	_	_
6-24	817-820	and	_	_	_	_
6-25	821-826	Black	person	new	_	_
6-26	827-829	et	_	_	_	_
6-27	830-833	al.	_	_	_	_
6-28	834-842	reported	_	_	_	_
6-29	843-847	that	_	_	_	_
6-30	848-850	43	person[41]	new[41]	_	_
6-31	851-852	%	person[41]	new[41]	_	_
6-32	853-855	of	person[41]	new[41]	_	_
6-33	856-862	horses	person[41]|animal	new[41]|giv	coref	7-18[53_0]
6-34	863-876	seroconverted	_	_	_	_
6-35	877-879	to	_	_	_	_
6-36	880-884	ERAV	abstract	giv	coref	7-12
6-37	885-891	within	_	_	_	_
6-38	892-893	7	time[44]	new[44]	_	_
6-39	894-900	months	time[44]	new[44]	_	_
6-40	901-903	of	time[44]	new[44]	_	_
6-41	904-912	entering	time[44]	new[44]	_	_
6-42	913-914	a	time[44]|place[46]	new[44]|new[46]	_	_
6-43	915-923	training	time[44]|event|place[46]	new[44]|giv|new[46]	coref	8-18[62_0]
6-44	924-930	stable	time[44]|place[46]	new[44]|new[46]	_	_
6-45	931-933	in	time[44]	new[44]	_	_
6-46	934-943	Australia	time[44]|place	new[44]|new	coref	27-8
6-47	944-945	.	_	_	_	_

#Text=A previous study in a training yard in Ireland indicated that ERAV infection was largely confined to two-year-old horses and was most prevalent in late winter and spring .
7-1	946-947	A	abstract[48]	giv[48]	ana	8-6[0_48]
7-2	948-956	previous	abstract[48]	giv[48]	_	_
7-3	957-962	study	abstract[48]	giv[48]	_	_
7-4	963-965	in	abstract[48]	giv[48]	_	_
7-5	966-967	a	abstract[48]|place[49]	giv[48]|giv[49]	coref	24-10[184_49]
7-6	968-976	training	abstract[48]|place[49]	giv[48]|giv[49]	_	_
7-7	977-981	yard	abstract[48]|place[49]	giv[48]|giv[49]	_	_
7-8	982-984	in	abstract[48]|place[49]	giv[48]|giv[49]	_	_
7-9	985-992	Ireland	abstract[48]|place[49]|place	giv[48]|giv[49]|new	coref	27-6
7-10	993-1002	indicated	_	_	_	_
7-11	1003-1007	that	_	_	_	_
7-12	1008-1012	ERAV	abstract|event[52]	giv|giv[52]	coref|coref	8-15|8-15[61_52]
7-13	1013-1022	infection	event[52]	giv[52]	_	_
7-14	1023-1026	was	_	_	_	_
7-15	1027-1034	largely	_	_	_	_
7-16	1035-1043	confined	_	_	_	_
7-17	1044-1046	to	_	_	_	_
7-18	1047-1059	two-year-old	animal[53]	giv[53]	coref	11-19[82_53]
7-19	1060-1066	horses	animal[53]	giv[53]	_	_
7-20	1067-1070	and	_	_	_	_
7-21	1071-1074	was	_	_	_	_
7-22	1075-1079	most	_	_	_	_
7-23	1080-1089	prevalent	_	_	_	_
7-24	1090-1092	in	_	_	_	_
7-25	1093-1097	late	time[54]	new[54]	_	_
7-26	1098-1104	winter	time[54]	new[54]	_	_
7-27	1105-1108	and	_	_	_	_
7-28	1109-1115	spring	time	new	_	_
7-29	1116-1117	.	_	_	_	_

#Text=However , we believe that this is the first investigation of the association between ERAV infection with interrupted training and failure to race .
8-1	1118-1125	However	_	_	_	_
8-2	1126-1127	,	_	_	_	_
8-3	1128-1130	we	person	acc	_	_
8-4	1131-1138	believe	_	_	_	_
8-5	1139-1143	that	_	_	_	_
8-6	1144-1148	this	abstract	giv	coref	4-5
8-7	1149-1151	is	_	_	_	_
8-8	1152-1155	the	abstract[58]	giv[58]	coref	9-8[65_0]
8-9	1156-1161	first	abstract[58]	giv[58]	_	_
8-10	1162-1175	investigation	abstract[58]	giv[58]	_	_
8-11	1176-1178	of	abstract[58]	giv[58]	_	_
8-12	1179-1182	the	abstract[58]|abstract[59]	giv[58]|new[59]	coref	18-19[135_59]
8-13	1183-1194	association	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
8-14	1195-1202	between	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
8-15	1203-1207	ERAV	abstract[58]|abstract[59]|abstract|event[61]	giv[58]|new[59]|giv|giv[61]	coref|coref	9-12|12-6[85_61]
8-16	1208-1217	infection	abstract[58]|abstract[59]|event[61]	giv[58]|new[59]|giv[61]	_	_
8-17	1218-1222	with	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
8-18	1223-1234	interrupted	abstract[58]|abstract[59]|event[62]	giv[58]|new[59]|giv[62]	coref	11-16[0_62]
8-19	1235-1243	training	abstract[58]|abstract[59]|event[62]	giv[58]|new[59]|giv[62]	_	_
8-20	1244-1247	and	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
8-21	1248-1255	failure	abstract[58]|abstract[59]|event[63]	giv[58]|new[59]|giv[63]	coref	18-26[137_63]
8-22	1256-1258	to	abstract[58]|abstract[59]|event[63]	giv[58]|new[59]|giv[63]	_	_
8-23	1259-1263	race	abstract[58]|abstract[59]|event[63]	giv[58]|new[59]|giv[63]	_	_
8-24	1264-1265	.	_	_	_	_

#Text=Over 55 % of the two-year-olds in the study seroconverted to ERAV in May and June and none of them raced at that time .
9-1	1266-1270	Over	person[64]	new[64]	_	_
9-2	1271-1273	55	person[64]	new[64]	_	_
9-3	1274-1275	%	person[64]	new[64]	_	_
9-4	1276-1278	of	person[64]	new[64]	_	_
9-5	1279-1282	the	person[64]	new[64]	_	_
9-6	1283-1296	two-year-olds	person[64]	new[64]	_	_
9-7	1297-1299	in	person[64]	new[64]	_	_
9-8	1300-1303	the	person[64]|abstract[65]	new[64]|giv[65]	coref	11-4[76_65]
9-9	1304-1309	study	person[64]|abstract[65]	new[64]|giv[65]	_	_
9-10	1310-1323	seroconverted	_	_	_	_
9-11	1324-1326	to	_	_	_	_
9-12	1327-1331	ERAV	abstract	giv	coref	11-11
9-13	1332-1334	in	_	_	_	_
9-14	1335-1338	May	time|time[68]	new|new[68]	ana|coref	9-20[0_68]|9-23[71_0]
9-15	1339-1342	and	time[68]	new[68]	_	_
9-16	1343-1347	June	time[68]	new[68]	_	_
9-17	1348-1351	and	_	_	_	_
9-18	1352-1356	none	event[69]	new[69]	_	_
9-19	1357-1359	of	event[69]	new[69]	_	_
9-20	1360-1364	them	event[69]|time	new[69]|giv	_	_
9-21	1365-1370	raced	_	_	_	_
9-22	1371-1373	at	_	_	_	_
9-23	1374-1378	that	time[71]	giv[71]	coref	18-30[139_71]
9-24	1379-1383	time	time[71]	giv[71]	_	_
9-25	1384-1385	.	_	_	_	_

#Text=In fact , only 29 % of the two-year-olds raced in their first season .
10-1	1386-1388	In	_	_	_	_
10-2	1389-1393	fact	_	_	_	_
10-3	1394-1395	,	_	_	_	_
10-4	1396-1400	only	person[72]	new[72]	_	_
10-5	1401-1403	29	person[72]	new[72]	_	_
10-6	1404-1405	%	person[72]	new[72]	_	_
10-7	1406-1408	of	person[72]	new[72]	_	_
10-8	1409-1412	the	person[72]	new[72]	_	_
10-9	1413-1426	two-year-olds	person[72]	new[72]	_	_
10-10	1427-1432	raced	_	_	_	_
10-11	1433-1435	in	_	_	_	_
10-12	1436-1441	their	person|event[74]	giv|new[74]	_	_
10-13	1442-1447	first	event[74]	new[74]	_	_
10-14	1448-1454	season	event[74]	new[74]	_	_
10-15	1455-1456	.	_	_	_	_

#Text=The results of this study suggest that the importance of ERAV in the interruption of training programmes for young horses may be underestimated .
11-1	1457-1460	The	abstract[75]	new[75]	coref	24-1[182_75]
11-2	1461-1468	results	abstract[75]	new[75]	_	_
11-3	1469-1471	of	abstract[75]	new[75]	_	_
11-4	1472-1476	this	abstract[75]|abstract[76]	new[75]|giv[76]	coref	13-2[86_76]
11-5	1477-1482	study	abstract[75]|abstract[76]	new[75]|giv[76]	_	_
11-6	1483-1490	suggest	_	_	_	_
11-7	1491-1495	that	_	_	_	_
11-8	1496-1499	the	abstract[77]	new[77]	_	_
11-9	1500-1510	importance	abstract[77]	new[77]	_	_
11-10	1511-1513	of	abstract[77]	new[77]	_	_
11-11	1514-1518	ERAV	abstract[77]|abstract	new[77]|giv	coref	12-6
11-12	1519-1521	in	abstract[77]	new[77]	_	_
11-13	1522-1525	the	abstract[77]|event[79]	new[77]|giv[79]	coref	19-17[144_79]
11-14	1526-1538	interruption	abstract[77]|event[79]	new[77]|giv[79]	_	_
11-15	1539-1541	of	abstract[77]|event[79]	new[77]|giv[79]	_	_
11-16	1542-1550	training	abstract[77]|event[79]|event|abstract[81]	new[77]|giv[79]|giv|new[81]	coref	15-14
11-17	1551-1561	programmes	abstract[77]|event[79]|abstract[81]	new[77]|giv[79]|new[81]	_	_
11-18	1562-1565	for	abstract[77]|event[79]|abstract[81]	new[77]|giv[79]|new[81]	_	_
11-19	1566-1571	young	abstract[77]|event[79]|abstract[81]|animal[82]	new[77]|giv[79]|new[81]|giv[82]	coref	21-4[158_82]
11-20	1572-1578	horses	abstract[77]|event[79]|abstract[81]|animal[82]	new[77]|giv[79]|new[81]|giv[82]	_	_
11-21	1579-1582	may	_	_	_	_
11-22	1583-1585	be	_	_	_	_
11-23	1586-1600	underestimated	_	_	_	_
11-24	1601-1602	.	_	_	_	_

#Text=Acute febrile respiratory disease following ERAV infection has been reported previously .
12-1	1603-1608	Acute	abstract[83]	giv[83]	coref	13-9[89_83]
12-2	1609-1616	febrile	abstract[83]	giv[83]	_	_
12-3	1617-1628	respiratory	abstract[83]	giv[83]	_	_
12-4	1629-1636	disease	abstract[83]	giv[83]	_	_
12-5	1637-1646	following	abstract[83]	giv[83]	_	_
12-6	1647-1651	ERAV	abstract[83]|abstract|event[85]	giv[83]|giv|giv[85]	coref|coref	15-1|18-7[132_85]
12-7	1652-1661	infection	abstract[83]|event[85]	giv[83]|giv[85]	_	_
12-8	1662-1665	has	_	_	_	_
12-9	1666-1670	been	_	_	_	_
12-10	1671-1679	reported	_	_	_	_
12-11	1680-1690	previously	_	_	_	_
12-12	1691-1692	.	_	_	_	_

#Text=In an experimental study , ERAV-inoculated ponies developed respiratory tract disease characterized by pyrexia , nasal discharge , adventitious lung sounds , and enlarged mandibular lymph nodes , which corresponded with an increase in antibody titres against the virus .
13-1	1693-1695	In	_	_	_	_
13-2	1696-1698	an	abstract[86]	giv[86]	coref	14-6[101_86]
13-3	1699-1711	experimental	abstract[86]	giv[86]	_	_
13-4	1712-1717	study	abstract[86]	giv[86]	_	_
13-5	1718-1719	,	_	_	_	_
13-6	1720-1735	ERAV-inoculated	animal[87]	new[87]	_	_
13-7	1736-1742	ponies	animal[87]	new[87]	_	_
13-8	1743-1752	developed	_	_	_	_
13-9	1753-1764	respiratory	object[88]|abstract[89]	new[88]|giv[89]	coref	13-38[99_89]
13-10	1765-1770	tract	object[88]|abstract[89]	new[88]|giv[89]	_	_
13-11	1771-1778	disease	abstract[89]	giv[89]	_	_
13-12	1779-1792	characterized	abstract[89]	giv[89]	_	_
13-13	1793-1795	by	abstract[89]	giv[89]	_	_
13-14	1796-1803	pyrexia	abstract[89]|abstract	giv[89]|new	_	_
13-15	1804-1805	,	abstract[89]	giv[89]	_	_
13-16	1806-1811	nasal	abstract[89]|event[91]	giv[89]|new[91]	_	_
13-17	1812-1821	discharge	abstract[89]|event[91]	giv[89]|new[91]	_	_
13-18	1822-1823	,	abstract[89]	giv[89]	_	_
13-19	1824-1836	adventitious	abstract[89]|abstract[93]	giv[89]|new[93]	_	_
13-20	1837-1841	lung	abstract[89]|object|abstract[93]	giv[89]|new|new[93]	_	_
13-21	1842-1848	sounds	abstract[89]|abstract[93]	giv[89]|new[93]	_	_
13-22	1849-1850	,	abstract[89]	giv[89]	_	_
13-23	1851-1854	and	abstract[89]	giv[89]	_	_
13-24	1855-1863	enlarged	abstract[89]|object[95]	giv[89]|new[95]	_	_
13-25	1864-1874	mandibular	abstract[89]|object[95]	giv[89]|new[95]	_	_
13-26	1875-1880	lymph	abstract[89]|person|object[95]	giv[89]|new|new[95]	_	_
13-27	1881-1886	nodes	abstract[89]|object[95]	giv[89]|new[95]	_	_
13-28	1887-1888	,	abstract[89]|object[95]	giv[89]|new[95]	_	_
13-29	1889-1894	which	abstract[89]|object[95]	giv[89]|new[95]	_	_
13-30	1895-1907	corresponded	abstract[89]|object[95]	giv[89]|new[95]	_	_
13-31	1908-1912	with	abstract[89]|object[95]	giv[89]|new[95]	_	_
13-32	1913-1915	an	abstract[89]|object[95]|event[96]	giv[89]|new[95]|new[96]	_	_
13-33	1916-1924	increase	abstract[89]|object[95]|event[96]	giv[89]|new[95]|new[96]	_	_
13-34	1925-1927	in	abstract[89]|object[95]|event[96]	giv[89]|new[95]|new[96]	_	_
13-35	1928-1936	antibody	abstract[89]|object[95]|event[96]|substance|abstract[98]	giv[89]|new[95]|new[96]|new|new[98]	_	_
13-36	1937-1943	titres	abstract[89]|object[95]|event[96]|abstract[98]	giv[89]|new[95]|new[96]|new[98]	_	_
13-37	1944-1951	against	abstract[89]|object[95]|event[96]|abstract[98]	giv[89]|new[95]|new[96]|new[98]	_	_
13-38	1952-1955	the	abstract[89]|object[95]|event[96]|abstract[98]|abstract[99]	giv[89]|new[95]|new[96]|new[98]|giv[99]	coref	15-9[107_99]
13-39	1956-1961	virus	abstract[89]|object[95]|event[96]|abstract[98]|abstract[99]	giv[89]|new[95]|new[96]|new[98]|giv[99]	_	_
13-40	1962-1963	.	_	_	_	_

#Text=The clinical signs observed during this study were associated with the seroconversions and there was no evidence of other viral infections .
14-1	1964-1967	The	abstract[100]	giv[100]	coref	21-23[163_100]
14-2	1968-1976	clinical	abstract[100]	giv[100]	_	_
14-3	1977-1982	signs	abstract[100]	giv[100]	_	_
14-4	1983-1991	observed	abstract[100]	giv[100]	_	_
14-5	1992-1998	during	abstract[100]	giv[100]	_	_
14-6	1999-2003	this	abstract[100]|abstract[101]	giv[100]|giv[101]	coref	16-6[117_101]
14-7	2004-2009	study	abstract[100]|abstract[101]	giv[100]|giv[101]	_	_
14-8	2010-2014	were	_	_	_	_
14-9	2015-2025	associated	_	_	_	_
14-10	2026-2030	with	_	_	_	_
14-11	2031-2034	the	abstract[102]	new[102]	coref	21-8[159_102]
14-12	2035-2050	seroconversions	abstract[102]	new[102]	_	_
14-13	2051-2054	and	_	_	_	_
14-14	2055-2060	there	_	_	_	_
14-15	2061-2064	was	_	_	_	_
14-16	2065-2067	no	abstract[103]	new[103]	_	_
14-17	2068-2076	evidence	abstract[103]	new[103]	_	_
14-18	2077-2079	of	abstract[103]	new[103]	_	_
14-19	2080-2085	other	abstract[103]|abstract[104]	new[103]|new[104]	coref	15-9[108_104]
14-20	2086-2091	viral	abstract[103]|abstract[104]	new[103]|new[104]	_	_
14-21	2092-2102	infections	abstract[103]|abstract[104]	new[103]|new[104]	_	_
14-22	2103-2104	.	_	_	_	_

#Text=ERAV may have been the primary cause of the respiratory disease and subsequent training loss , but it is more likely that the virus was a contributory factor in a multifactorial disorder .
15-1	2105-2109	ERAV	abstract	giv	coref	15-5[106_0]
15-2	2110-2113	may	_	_	_	_
15-3	2114-2118	have	_	_	_	_
15-4	2119-2123	been	_	_	_	_
15-5	2124-2127	the	abstract[106]	giv[106]	ana	15-18[0_106]
15-6	2128-2135	primary	abstract[106]	giv[106]	_	_
15-7	2136-2141	cause	abstract[106]	giv[106]	_	_
15-8	2142-2144	of	abstract[106]	giv[106]	_	_
15-9	2145-2148	the	abstract[106]|abstract[107]|abstract[108]	giv[106]|giv[107]|giv[108]	coref	15-23[112_107]
15-10	2149-2160	respiratory	abstract[106]|abstract[107]|abstract[108]	giv[106]|giv[107]|giv[108]	_	_
15-11	2161-2168	disease	abstract[106]|abstract[107]|abstract[108]	giv[106]|giv[107]|giv[108]	_	_
15-12	2169-2172	and	abstract[106]|abstract[108]	giv[106]|giv[108]	_	_
15-13	2173-2183	subsequent	abstract[106]|abstract[108]|event[110]	giv[106]|giv[108]|giv[110]	_	_
15-14	2184-2192	training	abstract[106]|abstract[108]|event|event[110]	giv[106]|giv[108]|giv|giv[110]	coref	19-19
15-15	2193-2197	loss	abstract[106]|abstract[108]|event[110]	giv[106]|giv[108]|giv[110]	_	_
15-16	2198-2199	,	_	_	_	_
15-17	2200-2203	but	_	_	_	_
15-18	2204-2206	it	abstract	giv	coref	18-24
15-19	2207-2209	is	_	_	_	_
15-20	2210-2214	more	_	_	_	_
15-21	2215-2221	likely	_	_	_	_
15-22	2222-2226	that	_	_	_	_
15-23	2227-2230	the	abstract[112]	giv[112]	coref	15-26[113_112]
15-24	2231-2236	virus	abstract[112]	giv[112]	_	_
15-25	2237-2240	was	_	_	_	_
15-26	2241-2242	a	abstract[113]	giv[113]	coref	20-22[0_113]
15-27	2243-2255	contributory	abstract[113]	giv[113]	_	_
15-28	2256-2262	factor	abstract[113]	giv[113]	_	_
15-29	2263-2265	in	abstract[113]	giv[113]	_	_
15-30	2266-2267	a	abstract[113]|abstract[114]	giv[113]|new[114]	_	_
15-31	2268-2282	multifactorial	abstract[113]|abstract[114]	giv[113]|new[114]	_	_
15-32	2283-2291	disorder	abstract[113]|abstract[114]	giv[113]|new[114]	_	_
15-33	2292-2293	.	_	_	_	_

#Text=The serology tests used in this study are sensitive and specific , but it is possible that other less common viruses , such as adenovirus and coronavirus , or even as-yet unidentified equine viruses , may have played a role .
16-1	2294-2297	The	abstract[116]	new[116]	_	_
16-2	2298-2306	serology	abstract|abstract[116]	new|new[116]	coref	24-2
16-3	2307-2312	tests	abstract[116]	new[116]	_	_
16-4	2313-2317	used	abstract[116]	new[116]	_	_
16-5	2318-2320	in	abstract[116]	new[116]	_	_
16-6	2321-2325	this	abstract[116]|abstract[117]	new[116]|giv[117]	ana	16-14[0_117]
16-7	2326-2331	study	abstract[116]|abstract[117]	new[116]|giv[117]	_	_
16-8	2332-2335	are	_	_	_	_
16-9	2336-2345	sensitive	_	_	_	_
16-10	2346-2349	and	_	_	_	_
16-11	2350-2358	specific	_	_	_	_
16-12	2359-2360	,	_	_	_	_
16-13	2361-2364	but	_	_	_	_
16-14	2365-2367	it	abstract	giv	coref	18-16[134_0]
16-15	2368-2370	is	_	_	_	_
16-16	2371-2379	possible	_	_	_	_
16-17	2380-2384	that	_	_	_	_
16-18	2385-2390	other	animal[119]	new[119]	coref	16-30[122_119]
16-19	2391-2395	less	animal[119]	new[119]	_	_
16-20	2396-2402	common	animal[119]	new[119]	_	_
16-21	2403-2410	viruses	animal[119]	new[119]	_	_
16-22	2411-2412	,	animal[119]	new[119]	_	_
16-23	2413-2417	such	animal[119]	new[119]	_	_
16-24	2418-2420	as	animal[119]	new[119]	_	_
16-25	2421-2431	adenovirus	animal[119]|animal	new[119]|new	_	_
16-26	2432-2435	and	animal[119]	new[119]	_	_
16-27	2436-2447	coronavirus	animal[119]|plant	new[119]|new	_	_
16-28	2448-2449	,	animal[119]	new[119]	_	_
16-29	2450-2452	or	animal[119]	new[119]	_	_
16-30	2453-2457	even	animal[119]|animal[122]	new[119]|giv[122]	coref	17-27[0_122]
16-31	2458-2464	as-yet	animal[119]|animal[122]	new[119]|giv[122]	_	_
16-32	2465-2477	unidentified	animal[119]|animal[122]	new[119]|giv[122]	_	_
16-33	2478-2484	equine	animal[119]|animal[122]	new[119]|giv[122]	_	_
16-34	2485-2492	viruses	animal[119]|animal[122]	new[119]|giv[122]	_	_
16-35	2493-2494	,	_	_	_	_
16-36	2495-2498	may	_	_	_	_
16-37	2499-2503	have	_	_	_	_
16-38	2504-2510	played	_	_	_	_
16-39	2511-2512	a	abstract[123]	new[123]	coref	18-3[131_123]
16-40	2513-2517	role	abstract[123]	new[123]	_	_
16-41	2518-2519	.	_	_	_	_

#Text=Previous studies have demonstrated the complexity of poor performance syndrome in Thoroughbred racehorses and that bacteria are more common and may be aetiologically more important than viruses .
17-1	2520-2528	Previous	abstract[124]	new[124]	coref	23-1[176_124]
17-2	2529-2536	studies	abstract[124]	new[124]	_	_
17-3	2537-2541	have	_	_	_	_
17-4	2542-2554	demonstrated	_	_	_	_
17-5	2555-2558	the	abstract[125]	new[125]	_	_
17-6	2559-2569	complexity	abstract[125]	new[125]	_	_
17-7	2570-2572	of	abstract[125]	new[125]	_	_
17-8	2573-2577	poor	abstract[125]|abstract[127]	new[125]|new[127]	_	_
17-9	2578-2589	performance	abstract[125]|abstract|abstract[127]	new[125]|new|new[127]	coref	22-25[175_0]
17-10	2590-2598	syndrome	abstract[125]|abstract[127]	new[125]|new[127]	_	_
17-11	2599-2601	in	abstract[125]|abstract[127]	new[125]|new[127]	_	_
17-12	2602-2614	Thoroughbred	abstract[125]|abstract[127]|animal[128]	new[125]|new[127]|giv[128]	_	_
17-13	2615-2625	racehorses	abstract[125]|abstract[127]|animal[128]	new[125]|new[127]|giv[128]	_	_
17-14	2626-2629	and	_	_	_	_
17-15	2630-2634	that	_	_	_	_
17-16	2635-2643	bacteria	substance	new	_	_
17-17	2644-2647	are	_	_	_	_
17-18	2648-2652	more	_	_	_	_
17-19	2653-2659	common	_	_	_	_
17-20	2660-2663	and	_	_	_	_
17-21	2664-2667	may	_	_	_	_
17-22	2668-2670	be	_	_	_	_
17-23	2671-2685	aetiologically	_	_	_	_
17-24	2686-2690	more	_	_	_	_
17-25	2691-2700	important	_	_	_	_
17-26	2701-2705	than	_	_	_	_
17-27	2706-2713	viruses	animal	giv	_	_
17-28	2714-2715	.	_	_	_	_

#Text=Unfortunately , the possible role of bacterial infection as a cofactor was not investigated in this study and the statistically significant association of ERAV with failure to race during the study period does not conclusively demonstrate causation .
18-1	2716-2729	Unfortunately	_	_	_	_
18-2	2730-2731	,	_	_	_	_
18-3	2732-2735	the	abstract[131]	giv[131]	_	_
18-4	2736-2744	possible	abstract[131]	giv[131]	_	_
18-5	2745-2749	role	abstract[131]	giv[131]	_	_
18-6	2750-2752	of	abstract[131]	giv[131]	_	_
18-7	2753-2762	bacterial	abstract[131]|event[132]	giv[131]|giv[132]	coref	23-6[178_132]
18-8	2763-2772	infection	abstract[131]|event[132]	giv[131]|giv[132]	_	_
18-9	2773-2775	as	abstract[131]|event[132]	giv[131]|giv[132]	_	_
18-10	2776-2777	a	abstract[131]|event[132]|abstract[133]	giv[131]|giv[132]|new[133]	_	_
18-11	2778-2786	cofactor	abstract[131]|event[132]|abstract[133]	giv[131]|giv[132]|new[133]	_	_
18-12	2787-2790	was	_	_	_	_
18-13	2791-2794	not	_	_	_	_
18-14	2795-2807	investigated	_	_	_	_
18-15	2808-2810	in	_	_	_	_
18-16	2811-2815	this	abstract[134]	giv[134]	coref	18-31[0_134]
18-17	2816-2821	study	abstract[134]	giv[134]	_	_
18-18	2822-2825	and	_	_	_	_
18-19	2826-2829	the	abstract[135]	giv[135]	_	_
18-20	2830-2843	statistically	abstract[135]	giv[135]	_	_
18-21	2844-2855	significant	abstract[135]	giv[135]	_	_
18-22	2856-2867	association	abstract[135]	giv[135]	_	_
18-23	2868-2870	of	abstract[135]	giv[135]	_	_
18-24	2871-2875	ERAV	abstract[135]|abstract	giv[135]|giv	coref	20-6
18-25	2876-2880	with	abstract[135]	giv[135]	_	_
18-26	2881-2888	failure	abstract[135]|event[137]	giv[135]|giv[137]	_	_
18-27	2889-2891	to	abstract[135]|event[137]	giv[135]|giv[137]	_	_
18-28	2892-2896	race	abstract[135]|event[137]	giv[135]|giv[137]	_	_
18-29	2897-2903	during	abstract[135]|event[137]	giv[135]|giv[137]	_	_
18-30	2904-2907	the	abstract[135]|event[137]|time[139]	giv[135]|giv[137]|giv[139]	coref	21-32[166_139]
18-31	2908-2913	study	abstract[135]|event[137]|abstract|time[139]	giv[135]|giv[137]|giv|giv[139]	coref	21-33
18-32	2914-2920	period	abstract[135]|event[137]|time[139]	giv[135]|giv[137]|giv[139]	_	_
18-33	2921-2925	does	_	_	_	_
18-34	2926-2929	not	_	_	_	_
18-35	2930-2942	conclusively	_	_	_	_
18-36	2943-2954	demonstrate	_	_	_	_
18-37	2955-2964	causation	abstract	new	ana	19-3
18-38	2965-2966	.	_	_	_	_

#Text=However , it is essential to determine which infectious agents are prevalent in populations that suffer interruption to training as a first step in assessing their true impact .
19-1	2967-2974	However	_	_	_	_
19-2	2975-2976	,	_	_	_	_
19-3	2977-2979	it	abstract	giv	_	_
19-4	2980-2982	is	_	_	_	_
19-5	2983-2992	essential	_	_	_	_
19-6	2993-2995	to	_	_	_	_
19-7	2996-3005	determine	_	_	_	_
19-8	3006-3011	which	person[142]	new[142]	_	_
19-9	3012-3022	infectious	person[142]	new[142]	_	_
19-10	3023-3029	agents	person[142]	new[142]	_	_
19-11	3030-3033	are	_	_	_	_
19-12	3034-3043	prevalent	_	_	_	_
19-13	3044-3046	in	_	_	_	_
19-14	3047-3058	populations	person[143]	new[143]	ana	19-26[0_143]
19-15	3059-3063	that	person[143]	new[143]	_	_
19-16	3064-3070	suffer	person[143]	new[143]	_	_
19-17	3071-3083	interruption	person[143]|event[144]	new[143]|giv[144]	_	_
19-18	3084-3086	to	person[143]|event[144]	new[143]|giv[144]	_	_
19-19	3087-3095	training	person[143]|event[144]|event	new[143]|giv[144]|giv	coref	20-16[155_0]
19-20	3096-3098	as	_	_	_	_
19-21	3099-3100	a	abstract[146]	new[146]	_	_
19-22	3101-3106	first	abstract[146]	new[146]	_	_
19-23	3107-3111	step	abstract[146]	new[146]	_	_
19-24	3112-3114	in	abstract[146]	new[146]	_	_
19-25	3115-3124	assessing	abstract[146]	new[146]	_	_
19-26	3125-3130	their	abstract[146]|person|abstract[148]	new[146]|giv|new[148]	coref	25-7[192_0]
19-27	3131-3135	true	abstract[146]|abstract[148]	new[146]|new[148]	_	_
19-28	3136-3142	impact	abstract[146]|abstract[148]	new[146]|new[148]	_	_
19-29	3143-3144	.	_	_	_	_

#Text=Lack of previous exposure to ERAV and stress associated with the change of environment and intensive training may have contributed to disease susceptibility .
20-1	3145-3149	Lack	abstract[149]	new[149]	_	_
20-2	3150-3152	of	abstract[149]	new[149]	_	_
20-3	3153-3161	previous	abstract[149]|abstract[150]	new[149]|giv[150]	_	_
20-4	3162-3170	exposure	abstract[149]|abstract[150]	new[149]|giv[150]	_	_
20-5	3171-3173	to	abstract[149]|abstract[150]	new[149]|giv[150]	_	_
20-6	3174-3178	ERAV	abstract[149]|abstract[150]|abstract	new[149]|giv[150]|giv	coref	21-11
20-7	3179-3182	and	abstract[149]	new[149]	_	_
20-8	3183-3189	stress	abstract[149]|abstract[152]	new[149]|new[152]	_	_
20-9	3190-3200	associated	abstract[149]|abstract[152]	new[149]|new[152]	_	_
20-10	3201-3205	with	abstract[149]|abstract[152]	new[149]|new[152]	_	_
20-11	3206-3209	the	abstract[149]|abstract[152]|event[153]	new[149]|new[152]|new[153]	_	_
20-12	3210-3216	change	abstract[149]|abstract[152]|event[153]	new[149]|new[152]|new[153]	_	_
20-13	3217-3219	of	abstract[149]|abstract[152]|event[153]	new[149]|new[152]|new[153]	_	_
20-14	3220-3231	environment	abstract[149]|abstract[152]|event[153]|abstract	new[149]|new[152]|new[153]|giv	_	_
20-15	3232-3235	and	abstract[149]|abstract[152]|event[153]	new[149]|new[152]|new[153]	_	_
20-16	3236-3245	intensive	abstract[149]|abstract[152]|event[153]|event[155]	new[149]|new[152]|new[153]|giv[155]	coref	27-48[0_155]
20-17	3246-3254	training	abstract[149]|abstract[152]|event[153]|event[155]	new[149]|new[152]|new[153]|giv[155]	_	_
20-18	3255-3258	may	_	_	_	_
20-19	3259-3263	have	_	_	_	_
20-20	3264-3275	contributed	_	_	_	_
20-21	3276-3278	to	_	_	_	_
20-22	3279-3286	disease	abstract|abstract[157]	giv|giv[157]	coref	21-26[164_0]
20-23	3287-3301	susceptibility	abstract[157]	giv[157]	_	_
20-24	3302-3303	.	_	_	_	_

#Text=In contrast to the two-year-old horses , no seroconversions to ERAV were observed in the three-year-old horses — they remained free of any signs of respiratory disease and raced successfully throughout the study period .
21-1	3304-3306	In	_	_	_	_
21-2	3307-3315	contrast	_	_	_	_
21-3	3316-3318	to	_	_	_	_
21-4	3319-3322	the	animal[158]	giv[158]	coref	21-15[161_158]
21-5	3323-3335	two-year-old	animal[158]	giv[158]	_	_
21-6	3336-3342	horses	animal[158]	giv[158]	_	_
21-7	3343-3344	,	_	_	_	_
21-8	3345-3347	no	abstract[159]	giv[159]	ana	21-19[0_159]
21-9	3348-3363	seroconversions	abstract[159]	giv[159]	_	_
21-10	3364-3366	to	abstract[159]	giv[159]	_	_
21-11	3367-3371	ERAV	abstract[159]|abstract	giv[159]|giv	coref	22-4
21-12	3372-3376	were	_	_	_	_
21-13	3377-3385	observed	_	_	_	_
21-14	3386-3388	in	_	_	_	_
21-15	3389-3392	the	animal[161]	giv[161]	coref	22-15[172_161]
21-16	3393-3407	three-year-old	animal[161]	giv[161]	_	_
21-17	3408-3414	horses	animal[161]	giv[161]	_	_
21-18	3415-3416	—	_	_	_	_
21-19	3417-3421	they	abstract	giv	_	_
21-20	3422-3430	remained	_	_	_	_
21-21	3431-3435	free	_	_	_	_
21-22	3436-3438	of	_	_	_	_
21-23	3439-3442	any	abstract[163]	giv[163]	coref	22-22[173_163]
21-24	3443-3448	signs	abstract[163]	giv[163]	_	_
21-25	3449-3451	of	abstract[163]	giv[163]	_	_
21-26	3452-3463	respiratory	abstract[163]|abstract[164]	giv[163]|giv[164]	coref	25-13[0_164]
21-27	3464-3471	disease	abstract[163]|abstract[164]	giv[163]|giv[164]	_	_
21-28	3472-3475	and	_	_	_	_
21-29	3476-3481	raced	_	_	_	_
21-30	3482-3494	successfully	_	_	_	_
21-31	3495-3505	throughout	_	_	_	_
21-32	3506-3509	the	time[166]	giv[166]	coref	24-13[187_166]
21-33	3510-3515	study	abstract|time[166]	giv|giv[166]	coref	24-16
21-34	3516-3522	period	time[166]	giv[166]	_	_
21-35	3523-3524	.	_	_	_	_

#Text=The seroconversion to ERAV in the four-year-old horse and the reinfection of two of the younger horses were not associated with clinical signs or reduced performance .
22-1	3525-3528	The	abstract[167]	new[167]	_	_
22-2	3529-3543	seroconversion	abstract[167]	new[167]	_	_
22-3	3544-3546	to	abstract[167]	new[167]	_	_
22-4	3547-3551	ERAV	abstract[167]|abstract	new[167]|giv	coref	23-6
22-5	3552-3554	in	abstract[167]	new[167]	_	_
22-6	3555-3558	the	abstract[167]|animal[169]	new[167]|new[169]	coref	25-7[0_169]
22-7	3559-3572	four-year-old	abstract[167]|animal[169]	new[167]|new[169]	_	_
22-8	3573-3578	horse	abstract[167]|animal[169]	new[167]|new[169]	_	_
22-9	3579-3582	and	_	_	_	_
22-10	3583-3586	the	event[170]	new[170]	coref	23-14[0_170]
22-11	3587-3598	reinfection	event[170]	new[170]	_	_
22-12	3599-3601	of	event[170]	new[170]	_	_
22-13	3602-3605	two	event[170]|abstract[171]	new[170]|new[171]	_	_
22-14	3606-3608	of	event[170]|abstract[171]	new[170]|new[171]	_	_
22-15	3609-3612	the	event[170]|abstract[171]|animal[172]	new[170]|new[171]|giv[172]	coref	25-16[0_172]
22-16	3613-3620	younger	event[170]|abstract[171]|animal[172]	new[170]|new[171]|giv[172]	_	_
22-17	3621-3627	horses	event[170]|abstract[171]|animal[172]	new[170]|new[171]|giv[172]	_	_
22-18	3628-3632	were	_	_	_	_
22-19	3633-3636	not	_	_	_	_
22-20	3637-3647	associated	_	_	_	_
22-21	3648-3652	with	_	_	_	_
22-22	3653-3661	clinical	abstract[173]|abstract[174]	giv[173]|giv[174]	coref	22-22[174_173]
22-23	3662-3667	signs	abstract[173]|abstract[174]	giv[173]|giv[174]	_	_
22-24	3668-3670	or	abstract[174]	giv[174]	_	_
22-25	3671-3678	reduced	abstract[174]|abstract[175]	giv[174]|giv[175]	_	_
22-26	3679-3690	performance	abstract[174]|abstract[175]	giv[174]|giv[175]	_	_
22-27	3691-3692	.	_	_	_	_

#Text=Experimental studies have indicated that ERAV infection stimulated a protective response and that reinfection is asymptomatic .
23-1	3693-3705	Experimental	abstract[176]	giv[176]	_	_
23-2	3706-3713	studies	abstract[176]	giv[176]	_	_
23-3	3714-3718	have	_	_	_	_
23-4	3719-3728	indicated	_	_	_	_
23-5	3729-3733	that	_	_	_	_
23-6	3734-3738	ERAV	abstract|event[178]	giv|giv[178]	coref|coref	24-6|25-4[190_178]
23-7	3739-3748	infection	event[178]	giv[178]	_	_
23-8	3749-3759	stimulated	_	_	_	_
23-9	3760-3761	a	abstract[179]	new[179]	_	_
23-10	3762-3772	protective	abstract[179]	new[179]	_	_
23-11	3773-3781	response	abstract[179]	new[179]	_	_
23-12	3782-3785	and	_	_	_	_
23-13	3786-3790	that	_	_	_	_
23-14	3791-3802	reinfection	event	giv	_	_
23-15	3803-3805	is	_	_	_	_
23-16	3806-3818	asymptomatic	_	_	_	_
23-17	3819-3820	.	_	_	_	_

#Text=The serology results indicate that ERAV was circulating in the yard throughout the six month study period .
24-1	3821-3824	The	abstract[182]	giv[182]	_	_
24-2	3825-3833	serology	abstract|abstract[182]	giv|giv[182]	_	_
24-3	3834-3841	results	abstract[182]	giv[182]	_	_
24-4	3842-3850	indicate	_	_	_	_
24-5	3851-3855	that	_	_	_	_
24-6	3856-3860	ERAV	abstract	giv	coref	25-4
24-7	3861-3864	was	_	_	_	_
24-8	3865-3876	circulating	_	_	_	_
24-9	3877-3879	in	_	_	_	_
24-10	3880-3883	the	place[184]	giv[184]	_	_
24-11	3884-3888	yard	place[184]	giv[184]	_	_
24-12	3889-3899	throughout	_	_	_	_
24-13	3900-3903	the	time[187]	giv[187]	coref	29-2[227_187]
24-14	3904-3907	six	time[185]|time[187]	new[185]|giv[187]	coref	26-21[204_185]
24-15	3908-3913	month	time[185]|time[187]	new[185]|giv[187]	_	_
24-16	3914-3919	study	abstract|time[187]	giv|giv[187]	coref	29-3
24-17	3920-3926	period	time[187]	giv[187]	_	_
24-18	3927-3928	.	_	_	_	_

#Text=The dynamics of ERAV infection in horse populations are poorly understood but virus persists in horses even in the presence of high levels of antibodies .
25-1	3929-3932	The	abstract[188]	new[188]	_	_
25-2	3933-3941	dynamics	abstract[188]	new[188]	_	_
25-3	3942-3944	of	abstract[188]	new[188]	_	_
25-4	3945-3949	ERAV	abstract[188]|abstract|event[190]	new[188]|giv|giv[190]	coref|coref	26-1|26-13[0_190]
25-5	3950-3959	infection	abstract[188]|event[190]	new[188]|giv[190]	_	_
25-6	3960-3962	in	abstract[188]	new[188]	_	_
25-7	3963-3968	horse	abstract[188]|animal|person[192]	new[188]|giv|giv[192]	coref	29-6[228_0]
25-8	3969-3980	populations	abstract[188]|person[192]	new[188]|giv[192]	_	_
25-9	3981-3984	are	_	_	_	_
25-10	3985-3991	poorly	_	_	_	_
25-11	3992-4002	understood	_	_	_	_
25-12	4003-4006	but	_	_	_	_
25-13	4007-4012	virus	abstract	giv	_	_
25-14	4013-4021	persists	_	_	_	_
25-15	4022-4024	in	_	_	_	_
25-16	4025-4031	horses	animal	giv	_	_
25-17	4032-4036	even	abstract[195]	new[195]	_	_
25-18	4037-4039	in	abstract[195]	new[195]	_	_
25-19	4040-4043	the	abstract[195]	new[195]	_	_
25-20	4044-4052	presence	abstract[195]	new[195]	_	_
25-21	4053-4055	of	abstract[195]	new[195]	_	_
25-22	4056-4060	high	abstract[195]|abstract[196]	new[195]|new[196]	_	_
25-23	4061-4067	levels	abstract[195]|abstract[196]	new[195]|new[196]	_	_
25-24	4068-4070	of	abstract[195]|abstract[196]	new[195]|new[196]	_	_
25-25	4071-4081	antibodies	abstract[195]|abstract[196]|substance	new[195]|new[196]|new	_	_
25-26	4082-4083	.	_	_	_	_

#Text=ERAV can be isolated from the blood for a few days post infection and from the nasopharynx and faeces for up to a month .
26-1	4084-4088	ERAV	abstract	giv	coref	27-10
26-2	4089-4092	can	_	_	_	_
26-3	4093-4095	be	_	_	_	_
26-4	4096-4104	isolated	_	_	_	_
26-5	4105-4109	from	_	_	_	_
26-6	4110-4113	the	substance[199]	new[199]	_	_
26-7	4114-4119	blood	substance[199]	new[199]	_	_
26-8	4120-4123	for	_	_	_	_
26-9	4124-4125	a	time[200]	new[200]	_	_
26-10	4126-4129	few	time[200]	new[200]	_	_
26-11	4130-4134	days	time[200]	new[200]	_	_
26-12	4135-4139	post	time[200]	new[200]	_	_
26-13	4140-4149	infection	time[200]|event	new[200]|giv	_	_
26-14	4150-4153	and	_	_	_	_
26-15	4154-4158	from	_	_	_	_
26-16	4159-4162	the	object[202]	new[202]	_	_
26-17	4163-4174	nasopharynx	object[202]	new[202]	_	_
26-18	4175-4178	and	_	_	_	_
26-19	4179-4185	faeces	object	new	_	_
26-20	4186-4189	for	_	_	_	_
26-21	4190-4192	up	time[204]	giv[204]	_	_
26-22	4193-4195	to	time[204]	giv[204]	_	_
26-23	4196-4197	a	time[204]	giv[204]	_	_
26-24	4198-4203	month	time[204]	giv[204]	_	_
26-25	4204-4205	.	_	_	_	_

#Text=Studies in the USA , Ireland and Australia detected ERAV in post-race urine samples at frequencies of 17 % , 29 % and 23 % , respectively , which led to a suggestion that the persistent presence of ERAV in urine may contribute to its maintenance in training yards .
27-1	4206-4213	Studies	event[205]	new[205]	_	_
27-2	4214-4216	in	event[205]	new[205]	_	_
27-3	4217-4220	the	event[205]|place[206]	new[205]|new[206]	_	_
27-4	4221-4224	USA	event[205]|place[206]	new[205]|new[206]	_	_
27-5	4225-4226	,	event[205]	new[205]	_	_
27-6	4227-4234	Ireland	event[205]|place	new[205]|giv	coref	30-9
27-7	4235-4238	and	event[205]	new[205]	_	_
27-8	4239-4248	Australia	event[205]|place	new[205]|giv	_	_
27-9	4249-4257	detected	_	_	_	_
27-10	4258-4262	ERAV	abstract	giv	coref	27-39
27-11	4263-4265	in	_	_	_	_
27-12	4266-4275	post-race	object[211]	new[211]	_	_
27-13	4276-4281	urine	substance|object[211]	new|new[211]	coref	27-41
27-14	4282-4289	samples	object[211]	new[211]	_	_
27-15	4290-4292	at	_	_	_	_
27-16	4293-4304	frequencies	abstract[212]	new[212]	_	_
27-17	4305-4307	of	abstract[212]	new[212]	_	_
27-18	4308-4310	17	abstract[212]|abstract[213]	new[212]|new[213]	_	_
27-19	4311-4312	%	abstract[212]|abstract[213]	new[212]|new[213]	_	_
27-20	4313-4314	,	abstract[212]	new[212]	_	_
27-21	4315-4317	29	abstract[212]|abstract[214]	new[212]|new[214]	_	_
27-22	4318-4319	%	abstract[212]|abstract[214]	new[212]|new[214]	_	_
27-23	4320-4323	and	abstract[212]	new[212]	_	_
27-24	4324-4326	23	abstract[212]|abstract[215]	new[212]|new[215]	_	_
27-25	4327-4328	%	abstract[212]|abstract[215]	new[212]|new[215]	_	_
27-26	4329-4330	,	abstract[212]|abstract[215]	new[212]|new[215]	_	_
27-27	4331-4343	respectively	abstract[212]|abstract[215]	new[212]|new[215]	_	_
27-28	4344-4345	,	abstract[212]|abstract[215]	new[212]|new[215]	_	_
27-29	4346-4351	which	abstract[212]|abstract[215]	new[212]|new[215]	_	_
27-30	4352-4355	led	abstract[212]|abstract[215]	new[212]|new[215]	_	_
27-31	4356-4358	to	abstract[212]|abstract[215]	new[212]|new[215]	_	_
27-32	4359-4360	a	abstract[212]|abstract[215]|abstract[216]	new[212]|new[215]|new[216]	ana	27-45[0_216]
27-33	4361-4371	suggestion	abstract[212]|abstract[215]|abstract[216]	new[212]|new[215]|new[216]	_	_
27-34	4372-4376	that	abstract[212]|abstract[215]|abstract[216]	new[212]|new[215]|new[216]	_	_
27-35	4377-4380	the	abstract[212]|abstract[215]|abstract[216]|abstract[217]	new[212]|new[215]|new[216]|new[217]	_	_
27-36	4381-4391	persistent	abstract[212]|abstract[215]|abstract[216]|abstract[217]	new[212]|new[215]|new[216]|new[217]	_	_
27-37	4392-4400	presence	abstract[212]|abstract[215]|abstract[216]|abstract[217]	new[212]|new[215]|new[216]|new[217]	_	_
27-38	4401-4403	of	abstract[212]|abstract[215]|abstract[216]|abstract[217]	new[212]|new[215]|new[216]|new[217]	_	_
27-39	4404-4408	ERAV	abstract[212]|abstract[215]|abstract[216]|abstract[217]|abstract	new[212]|new[215]|new[216]|new[217]|giv	coref	30-12
27-40	4409-4411	in	abstract[212]|abstract[215]|abstract[216]|abstract[217]	new[212]|new[215]|new[216]|new[217]	_	_
27-41	4412-4417	urine	abstract[212]|abstract[215]|abstract[216]|abstract[217]|substance	new[212]|new[215]|new[216]|new[217]|giv	coref	28-6
27-42	4418-4421	may	abstract[212]|abstract[215]|abstract[216]	new[212]|new[215]|new[216]	_	_
27-43	4422-4432	contribute	abstract[212]|abstract[215]|abstract[216]	new[212]|new[215]|new[216]	_	_
27-44	4433-4435	to	abstract[212]|abstract[215]|abstract[216]	new[212]|new[215]|new[216]	_	_
27-45	4436-4439	its	abstract[212]|abstract[215]|abstract[216]|abstract|abstract[221]	new[212]|new[215]|new[216]|giv|new[221]	_	_
27-46	4440-4451	maintenance	abstract[212]|abstract[215]|abstract[216]|abstract[221]	new[212]|new[215]|new[216]|new[221]	_	_
27-47	4452-4454	in	abstract[212]|abstract[215]|abstract[216]|abstract[221]	new[212]|new[215]|new[216]|new[221]	_	_
27-48	4455-4463	training	abstract[212]|abstract[215]|abstract[216]|abstract[221]|event|place[223]	new[212]|new[215]|new[216]|new[221]|giv|new[223]	_	_
27-49	4464-4469	yards	abstract[212]|abstract[215]|abstract[216]|abstract[221]|place[223]	new[212]|new[215]|new[216]|new[221]|new[223]	_	_
27-50	4470-4471	.	_	_	_	_

#Text=ERBV was not detected in urine .
28-1	4472-4476	ERBV	abstract	new	coref	29-11
28-2	4477-4480	was	_	_	_	_
28-3	4481-4484	not	_	_	_	_
28-4	4485-4493	detected	_	_	_	_
28-5	4494-4496	in	_	_	_	_
28-6	4497-4502	urine	substance	giv	_	_
28-7	4503-4504	.	_	_	_	_

#Text=During this study period , only one horse seroconverted to ERBV .
29-1	4505-4511	During	_	_	_	_
29-2	4512-4516	this	time[227]	giv[227]	_	_
29-3	4517-4522	study	abstract|time[227]	giv|giv[227]	coref	30-5[232_0]
29-4	4523-4529	period	time[227]	giv[227]	_	_
29-5	4530-4531	,	_	_	_	_
29-6	4532-4536	only	animal[228]	giv[228]	_	_
29-7	4537-4540	one	animal[228]	giv[228]	_	_
29-8	4541-4546	horse	animal[228]	giv[228]	_	_
29-9	4547-4560	seroconverted	animal	new	_	_
29-10	4561-4563	to	_	_	_	_
29-11	4564-4568	ERBV	abstract	giv	ana	30-1
29-12	4569-4570	.	_	_	_	_

#Text=This was consistent with an earlier study in Ireland in which ERAV was found to be more commonly detected than ERBV .
30-1	4571-4575	This	abstract	giv	coref	30-21
30-2	4576-4579	was	_	_	_	_
30-3	4580-4590	consistent	_	_	_	_
30-4	4591-4595	with	_	_	_	_
30-5	4596-4598	an	abstract[232]	giv[232]	_	_
30-6	4599-4606	earlier	abstract[232]	giv[232]	_	_
30-7	4607-4612	study	abstract[232]	giv[232]	_	_
30-8	4613-4615	in	abstract[232]	giv[232]	_	_
30-9	4616-4623	Ireland	abstract[232]|place	giv[232]|giv	_	_
30-10	4624-4626	in	abstract[232]	giv[232]	_	_
30-11	4627-4632	which	abstract[232]	giv[232]	_	_
30-12	4633-4637	ERAV	abstract[232]|abstract	giv[232]|giv	coref	31-3
30-13	4638-4641	was	abstract[232]	giv[232]	_	_
30-14	4642-4647	found	abstract[232]	giv[232]	_	_
30-15	4648-4650	to	abstract[232]	giv[232]	_	_
30-16	4651-4653	be	abstract[232]	giv[232]	_	_
30-17	4654-4658	more	abstract[232]	giv[232]	_	_
30-18	4659-4667	commonly	abstract[232]	giv[232]	_	_
30-19	4668-4676	detected	abstract[232]	giv[232]	_	_
30-20	4677-4681	than	_	_	_	_
30-21	4682-4686	ERBV	abstract	giv	coref	31-5
30-22	4687-4688	.	_	_	_	_

#Text=Co-circulation of ERAV and ERBV was also reported previously .
31-1	4689-4703	Co-circulation	abstract[236]	new[236]	_	_
31-2	4704-4706	of	abstract[236]	new[236]	_	_
31-3	4707-4711	ERAV	abstract[236]|abstract	new[236]|giv	_	_
31-4	4712-4715	and	abstract[236]	new[236]	_	_
31-5	4716-4720	ERBV	abstract[236]|abstract	new[236]|giv	_	_
31-6	4721-4724	was	_	_	_	_
31-7	4725-4729	also	_	_	_	_
31-8	4730-4738	reported	_	_	_	_
31-9	4739-4749	previously	_	_	_	_
31-10	4750-4751	.	_	_	_	_
